New cocktail therapy targets liver cancer that resists immunotherapy
NCT ID NCT07157306
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of three drugs—gecacitinib, donafenib, and a PD-1 inhibitor—as a second-line treatment for people with advanced liver cancer that did not respond to initial immunotherapy. The study will enroll 35 participants and measure how well the treatment shrinks tumors and controls the disease, while also tracking side effects. The goal is to see if this drug cocktail can offer a new option when standard immunotherapy stops working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gecacitinib, donafenib, and a PD-1 inhibitor (a type of immunotherapy)
What this could lead to
If successful, this could offer a new second-line treatment option for people with advanced liver cancer whose disease worsened after initial immunotherapy.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply widely. The combination of three drugs also raises the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China